An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.

Exclusion Criteria

• •Previous anticancer treatment within 4 weeks prior to initiation of study treatment
• •Prior allogeneic stem cell or solid organ transplant
• •Treatment with systemic immunostimulatory agents within 4 weeks prior to initiation of study treatment
• •Use of any live vaccines against infectious diseases within 28 days of first dose.
• •Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
• •Current treatment with anti-viral therapy for HBV
• •Structurally unstable bone lesions suggesting impending fracture
• •History or leptomeningeal disease
• •History of idiopathic pulmonary fibrosis, organizing pneumonia, drug induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan
• •History of malignancy other than colorectal cancer within 2 years prior to screening, except for malignancies such as non-melanoma skin carcinoma or ductal carcinoma in situ
• •Active tuberculosis
• •Treatment with therapeutic oral or intravenous (IV) antibiotics within 2 weeks prior to initiating study treatment
• •Severe infection within 4 weeks (28 days) prior to initiation of study treatment
• •Significant cardiovascular disease, unstable or new onset of angina within 3 months prior to initiation of treatment, or myocardial infarction within 6 months prior to study treatment or unstable arrhythmia
• •Major surgical procedures, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for major surgical procedure during the study
• •Known allergy or hypersensitivity to any of the study drugs or their excipients
• •Inability to swallow medications
• •Malabsorption condition that would alter the absorption of orally administered medications
• •Evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding (i.e., in the absence of therapeutic anticoagulation)
• •Prior treatment with an agent targeting the adenosine pathway
• •Active or history of autoimmune disease or immune deficiency, including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain Barré syndrome, or multiple sclerosis
• •Prior treatment with immune checkpoint blockade therapies including anti-cytotoxic T lymphocyte-associated protein-4, anti PD-1, and anti-PD-L1 therapeutic antibodies
• •Mutation in the BRAF oncogene. Patients with unknown BRAF status will be required to undergo testing at a local laboratory and provide results at screening